LOGIN  |  REGISTER
Recursion
Terns Pharmaceuticals

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

April 24, 2025 | Last Trade: US$37.29 0.09 -0.24

LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts!®

Kiniksa Investor Contact
Jonathan Kirshenbaum
(781) 829-3949
This email address is being protected from spambots. You need JavaScript enabled to view it.

Kiniksa Media Contact
Tyler Gagnon
(781) 431-9100
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page